DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00005091 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: exatecan mesylate

Sponsor

Daiichi Pharmaceuticals